{"id":836606,"date":"2025-04-11T08:43:01","date_gmt":"2025-04-11T12:43:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/"},"modified":"2025-04-11T08:43:01","modified_gmt":"2025-04-11T12:43:01","slug":"immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/","title":{"rendered":"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA’s Shift to Non-Animal Testing Methods"},"content":{"rendered":"

<\/p>\n

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA’s Shift to Non-Animal Testing Methods<\/b><\/p>\n

AUSTIN, Texas–(BUSINESS WIRE<\/a>)–
\nImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration\u2019s (FDA) recent decision<\/a> to phase out animal testing requirements for monoclonal antibodies and other pharmaceutical products.\n<\/p>\n

\nThe FDA\u2019s announcement marks a significant advancement in regulatory modernization and aligns fully with ImmunoPrecise\u2019s mission to revolutionize drug discovery and development processes through cutting-edge, human-relevant technologies, including its proprietary AI platform, LENSai\u2122.\n<\/p>\n

\n\u201cThis policy shift reflects a growing global recognition that traditional animal models are often inadequate in predicting human biology,\u201d said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. \u201cIPA has long championed the transition toward more ethical, efficient, and accurate methodologies. Our AI-powered LENSai\u2122 platform and suite of integrated discovery tools were designed precisely to support this new era of translational science.\u201d\n<\/p>\n

\nIPA provides validated AI-driven methodologies that directly align with the FDA’s shift towards New Approach Methodologies (NAMs). These advanced tools effectively address critical drug development challenges, including safety, toxicity, immunogenicity, and efficacy, by leveraging sophisticated predictive capabilities:\n<\/p>\n

    \n
  1. \nSafety and Toxicity Prediction: IPA\u2019s LENSai platform utilizes AI analytics to accurately predict potential toxicities by mapping drug interactions across the human proteome, significantly reducing the reliance on animal models.\n<\/li>\n
  2. \nImmunogenicity Screening: The platform identifies immunogenic hotspots and predicts potential adverse immune responses, reducing the risk of anti-drug antibody formation and optimizing patient-specific strategies.\n<\/li>\n
  3. \nKnowledge Graphs for Drug Efficacy: IPA\u2019s semantic knowledge graphs integrate biological data and scientific literature, enabling precise predictions of drug efficacy and interactions in human systems.\n<\/li>\n<\/ol>\n

    \nThrough transitioning from animal testing to AI-driven methodologies, IPA aims to streamline preclinical workflows, reduce development costs, uphold higher ethical standards, and support regulatory compliance in line with the FDA\u2019s NAMs framework.\n<\/p>\n

    About ImmunoPrecise Antibodies Ltd.<\/b><\/p>\n

    \nImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the \u201cIPA Family\u201d).\n<\/p>\n

    Forward-Looking Statements<\/i><\/p>\n

    \nThis press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements often include words such as \u201cexpects,\u201d \u201cintends,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d or variations thereof, or state that certain actions, events, or results \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d or \u201cmight\u201d occur. These statements relate to, among other things, the anticipated benefits of IPA\u2019s AI-driven methodologies, the integration of LENSai and BioStrand\u2019s platforms into drug discovery, and the potential impact of regulatory shifts on IPA\u2019s business and product development.\n<\/p>\n

    \nAlthough the Company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to factors largely beyond the Company\u2019s control, including but not limited to scientific and technological developments, regulatory requirements, financial and operational risks, and competitive dynamics.\n<\/p>\n

    \nForward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information on risks and uncertainties can be found in the Company\u2019s Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company\u2019s SEDAR+ profile at www.sedarplus.ca<\/a> and EDGAR profile at www.sec.gov\/edgar<\/a>). Should any of these risks materialize, actual results could vary significantly.\n<\/p>\n

    \nReaders are cautioned not to place undue reliance on forward-looking statements, which reflect the Company\u2019s expectations only as of the date of this release. The Company assumes no obligation to update or revise these statements, except as required by law.\n<\/p>\n

    \"\"<\/p>\n

    View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250411220656\/en\/<\/a><\/span><\/p>\n

    Investor Relations Contact
    \n<\/b>
    investors@ipatherapeutics.com<\/a><\/p>\n

    KEYWORDS:<\/b> United States North America Canada Texas<\/p>\n

    INDUSTRY KEYWORDS:<\/b> Technology Infectious Diseases FDA Health Technology Software Biotechnology Pharmaceutical Health Data Management Artificial Intelligence<\/p>\n

    MEDIA:<\/b><\/p>\n\n\n\n\n
    Logo<\/b><\/font><\/td>\n<\/tr>\n
    \"Logo\"<\/td>\n<\/tr>\n
    <\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

    ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA’s Shift to Non-Animal Testing Methods AUSTIN, Texas–(BUSINESS WIRE)– ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration\u2019s (FDA) recent decision to phase out animal testing requirements for monoclonal antibodies and other pharmaceutical products. The FDA\u2019s announcement marks a significant advancement in regulatory modernization and aligns fully with ImmunoPrecise\u2019s mission to revolutionize drug discovery and development processes through cutting-edge, human-relevant technologies, including its proprietary AI platform, LENSai\u2122. \u201cThis policy shift reflects a growing global recognition that traditional animal models are often inadequate in predicting human biology,\u201d said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. \u201cIPA has … <\/p>\n

    Continue reading “ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA’s Shift to Non-Animal Testing Methods”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-836606","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA's Shift to Non-Animal Testing Methods - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA's Shift to Non-Animal Testing Methods - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA’s Shift to Non-Animal Testing Methods AUSTIN, Texas–(BUSINESS WIRE)– ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration\u2019s (FDA) recent decision to phase out animal testing requirements for monoclonal antibodies and other pharmaceutical products. The FDA\u2019s announcement marks a significant advancement in regulatory modernization and aligns fully with ImmunoPrecise\u2019s mission to revolutionize drug discovery and development processes through cutting-edge, human-relevant technologies, including its proprietary AI platform, LENSai\u2122. \u201cThis policy shift reflects a growing global recognition that traditional animal models are often inadequate in predicting human biology,\u201d said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. \u201cIPA has … Continue reading "ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA’s Shift to Non-Animal Testing Methods"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-11T12:43:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250411220656r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA’s Shift to Non-Animal Testing Methods\",\"datePublished\":\"2025-04-11T12:43:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\\\/\"},\"wordCount\":733,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250411220656r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\\\/\",\"name\":\"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA's Shift to Non-Animal Testing Methods - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250411220656r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-04-11T12:43:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250411220656r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250411220656r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA’s Shift to Non-Animal Testing Methods\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA's Shift to Non-Animal Testing Methods - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/","og_locale":"en_US","og_type":"article","og_title":"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA's Shift to Non-Animal Testing Methods - Market Newsdesk","og_description":"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA’s Shift to Non-Animal Testing Methods AUSTIN, Texas–(BUSINESS WIRE)– ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration\u2019s (FDA) recent decision to phase out animal testing requirements for monoclonal antibodies and other pharmaceutical products. The FDA\u2019s announcement marks a significant advancement in regulatory modernization and aligns fully with ImmunoPrecise\u2019s mission to revolutionize drug discovery and development processes through cutting-edge, human-relevant technologies, including its proprietary AI platform, LENSai\u2122. \u201cThis policy shift reflects a growing global recognition that traditional animal models are often inadequate in predicting human biology,\u201d said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. \u201cIPA has … Continue reading \"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA’s Shift to Non-Animal Testing Methods\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-11T12:43:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250411220656r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA’s Shift to Non-Animal Testing Methods","datePublished":"2025-04-11T12:43:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/"},"wordCount":733,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250411220656r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/","name":"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA's Shift to Non-Animal Testing Methods - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250411220656r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-04-11T12:43:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250411220656r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250411220656r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-fdas-shift-to-non-animal-testing-methods\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai\u2122 with FDA’s Shift to Non-Animal Testing Methods"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=836606"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836606\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=836606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=836606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=836606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}